Oral hypoxia–inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD
R Provenzano, A Besarab, CH Sun… - Clinical Journal of the …, 2016 - journals.lww.com
Results Of the 145 patients enrolled, 143 were evaluable for efficacy. Overall, 92% of
patients achieved hemoglobin response. Higher compared with lower starting doses led to …
patients achieved hemoglobin response. Higher compared with lower starting doses led to …
Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study
S Fishbane, MA El-Shahawy… - Journal of the …, 2021 - journals.lww.com
Background Current anemia therapies for patients with non–dialysis-dependent CKD may
require injection and medical visits. Roxadustat, an oral hypoxia-inducible factor prolyl …
require injection and medical visits. Roxadustat, an oral hypoxia-inducible factor prolyl …
Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan
T Akizawa, M Iwasaki, Y Yamaguchi… - Journal of the …, 2020 - journals.lww.com
Background Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor
approved in China for dialysis-dependent CKD anemia. Methods This phase 3, 24-week …
approved in China for dialysis-dependent CKD anemia. Methods This phase 3, 24-week …
[HTML][HTML] Roxadustat for CKD-related anemia in non-dialysis patients
DW Coyne, SD Roger, SK Shin, SG Kim… - Kidney international …, 2021 - Elsevier
Introduction Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that
stimulates erythropoiesis and improves iron metabolism. We assessed the efficacy and …
stimulates erythropoiesis and improves iron metabolism. We assessed the efficacy and …
[HTML][HTML] Phase 3 study of roxadustat to treat anemia in non–dialysis-dependant CKD
T Akizawa, M Iwasaki, T Otsuka, Y Yamaguchi… - Kidney international …, 2021 - Elsevier
Introduction Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that
has demonstrated safety and efficacy versus placebo in phase III trials in patients with …
has demonstrated safety and efficacy versus placebo in phase III trials in patients with …
Roxadustat (FG-4592): correction of anemia in incident dialysis patients
A Besarab, E Chernyavskaya, I Motylev… - Journal of the …, 2016 - journals.lww.com
Safety concerns with erythropoietin analogues and intravenous (IV) iron for treatment of
anemia in CKD necessitate development of safer therapies. Roxadustat (FG-4592) is an …
anemia in CKD necessitate development of safer therapies. Roxadustat (FG-4592) is an …
[HTML][HTML] Roxadustat for anemia in patients with kidney disease not receiving dialysis
N Chen, C Hao, X Peng, H Lin, A Yin… - … England Journal of …, 2019 - Mass Medical Soc
Abstract Background Roxadustat (FG-4592) is an oral inhibitor of hypoxia-inducible factor
(HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. In …
(HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. In …
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS)
E Shutov, W Sułowicz, C Esposito… - Nephrology Dialysis …, 2021 - academic.oup.com
Background Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3 …
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3 …
Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial
T Akizawa, M Iwasaki, T Otsuka, M Reusch… - Advances in Therapy, 2019 - Springer
Introduction This study evaluated efficacy and safety/tolerability of roxadustat, an oral
hypoxia-inducible factor prolyl hydroxylase inhibitor, in Japanese anemic non-dialysis …
hypoxia-inducible factor prolyl hydroxylase inhibitor, in Japanese anemic non-dialysis …
A phase 3, multicenter, randomized, two-arm, open-label study of intermittent oral dosing of roxadustat for the treatment of anemia in Japanese erythropoiesis …
T Akizawa, Y Yamaguchi, T Otsuka, M Reusch - Nephron, 2020 - karger.com
Introduction: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor
approved for the treatment of anemia in Japan for patients with dialysis-dependent (DD) …
approved for the treatment of anemia in Japan for patients with dialysis-dependent (DD) …